|
Early surrogate measures for ablative therapies for intermediate-risk prostate cancer patients. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Varian Medical Systems; ViewRay; ViewRay |
Consulting or Advisory Role - Janssen |
|
|
No Relationships to Disclose |
|
Constantine Anastasios Mantz |
Employment - 21st Century Oncology |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Accuray; Varian Medical Systems; ViewRay |
Consulting or Advisory Role - Accuray |
Research Funding - Accuray |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen Oncology; Sanofi; Tersera |
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Janssen Oncology; Sanofi; TerSera |
Research Funding - Tersera |
Patents, Royalties, Other Intellectual Property - Prostate immobilization device (GU-Lok) |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Sanofi; Tersera |